ABA Chemicals Corporation (300261.SZ) plans to raise no more than 841 million yuan through a private placement of stocks.

19:17 11/08/2026

Yabont Chemical (300261.SZ) announced its plan to issue A shares to specific targets in 2026, with the total amount of funds raised from this issuance not exceeding 841 million yuan (including the principal). After deducting the issuance costs, the funds will be used for the following projects: a pilot project for the annual production of 35 tons of high-end pharmaceutical intermediates, a new project for the annual production of 2,019 tons of active pharmaceutical ingredients and intermediates (Phase I), a new project for the annual production of 140 tons of pharmaceutical active ingredients, a new project for the annual production of 50 tons of linagliptin and 2 tons of SERD inhibitors, as well as the construction of a research and development center and to supplement working capital.

ABA Chemicals Corporation (300261.SZ) released a plan for the issuance of A-shares to specific targets in 2026, aiming to raise a total of no more than 841 million yuan (inclusive of this amount) from the issuance of shares, which, after deducting issuance costs, will be used for the following projects: a pilot project for the annual production of 35 tons of high-end pharmaceutical intermediates, a new project for the annual production of 2,019 tons of raw materials and intermediates (Phase I), a new project for the annual production of 140 tons of pharmaceutical raw materials, a new project for the annual production of 50 tons of Regagliptin and 2 tons of SERD inhibitors, as well as the construction of a research and development center and to supplement working capital.

In the first seven months, CHINA JINMAO (00817) accumulated a signed sales amount of 66.702 billion yuan, an increase of 7.92% year-on-year.

CNE TECH CORP (00611) issued a profit warning, expecting a mid-term net profit of no less than 30 million yuan, a decrease of no more than 65% compared to the same period last year.

CSPC PHARMA (01093): The Phase I clinical trial of SYS 6063 for the treatment of refractory relapse systemic lupus erythematosus has officially launched at the first center in China.

In the first seven months, CHINA JINMAO (00817) accumulated a signed sales amount of 66.702 billion yuan, an increase of 7.92% year-on-year.

CNE TECH CORP (00611) issued a profit warning, expecting a mid-term net profit of no less than 30 million yuan, a decrease of no more than 65% compared to the same period last year.

CSPC PHARMA (01093): The Phase I clinical trial of SYS 6063 for the treatment of refractory relapse systemic lupus erythematosus has officially launched at the first center in China.